AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: FBLG
Report Date: 2026-05-11
Full Report: https://amaly.io/stock/FBLG

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: FibroBiologics, Inc. (FBLG) is a clinical-stage biotechnology company developing fibroblast-based cell therapies for degenerative diseases and other conditions. The company's core business activities are Shariah-compliant, focusing on healthcare innovation without involvement in prohibited sectors. Financial screening shows compliance with most ratio thresholds except AAOIFI's liquidity criterion. No index inclusion due to small market capitalization and liquidity constraints, leading to an overall non-compliant status. Purification is not required, and ESG factors align well with Islamic principles.

Primary Compliance Concerns:
- Liquidity ratio exceeds AAOIFI threshold (30.26% vs. 30%)
- Insufficient data for precise income ratio calculations
- Exclusion from major Shariah indices due to size and liquidity

Purification Requirement: 0.00%
Index Inclusion: Not included in S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, or Dow Jones Islamic Market (DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 24.8%
Liquidity Ratio: 30.3%
Interest Income Ratio: 0.0%
Purification Required: 0.00%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-12-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q3 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-28T12:00:00Z

---
Full interactive report: https://amaly.io/stock/FBLG
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.